Dr. Mandelli studies treatments for pancreatic neuroendocrine tumors, which are rare tumors located in the pancreas. One of the key techniques he explores is endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA). This procedure uses ultrasound to guide a radiofrequency device to destroy tumor cells while minimizing damage to surrounding healthy tissue. His research aims to make this treatment accessible and effective for patients, particularly for those with smaller tumors that might be harder to treat with traditional surgery.
Key findings
In a review of 61 patients treated with EUS-RFA, 96% had positive results from the procedure.
Only 13.7% of the patients experienced mild adverse events, indicating a high safety profile.
Smaller tumors, particularly those under 18 mm, had an 80% chance of responding well to EUS-RFA.
Frequently asked questions
Does Dr. Mandelli study pancreatic tumors?
Yes, Dr. Mandelli specializes in research on pancreatic neuroendocrine tumors.
What treatment does Dr. Mandelli research for these tumors?
He focuses on endoscopic ultrasound-guided radiofrequency ablation, a minimally invasive option.
Is Dr. Mandelli's work relevant for patients with small pancreatic tumors?
Yes, his research particularly helps patients with smaller tumors, offering effective treatment options.
Publications in plain English
Linear EUS Accuracy in Preoperative Staging of Gastric Cancer: A Retrospective Multicenter Study.
2023
Diagnostics (Basel, Switzerland)
de Nucci G, Gabbani T, Impellizzeri G, Deiana S, Biancheri P +7 more
Plain English This study examined how well two imaging methods, linear endoscopic ultrasound (L-EUS) and contrast-enhanced computed tomography (CECT), accurately assess the stage of gastric cancer before surgery. Researchers found that L-EUS had a perfect accuracy of 100% in identifying early-stage tumors (T1) and performed significantly better overall compared to CECT, especially in determining lymph node involvement (85% accuracy for L-EUS vs. 61% for CECT). These findings are important because better staging helps doctors choose the most effective treatment for patients with gastric cancer.
Who this helps: This helps patients with gastric cancer by ensuring they receive more accurate assessments before treatment.
Fine Needle Aspiration versus Fine Needle Biopsy of Biliopancreatic Lesions: Are They Really Opposing Techniques or Can They Be Complementary? Our Experience in a Large Cohort of Cases from a Single Institution.
2021
Acta cytologica
Nicola M, Onorati M, Albertoni MM, Bianchi CL, De Nucci G +3 more
Plain English This study looked at two diagnostic methods, fine needle aspiration (FNA) and fine needle biopsy (FNB), for detecting problems in the pancreas and biliary system. The researchers analyzed data from 469 procedures and found that FNA had a success rate of 98.9% while FNB had a perfect success rate of 100%. They discovered that nearly half (48.1%) of the pancreatic lesions were cancerous, compared to 33.8% of biliary lesions, and noted that FNA works best for pancreatic tumors while FNB can provide more detailed information.
Who this helps: Patients with biliopancreatic lesions benefit from knowing which diagnostic technique is most effective.
Epidemiology, clinical features and diagnostic work-up of cystic neoplasms of the pancreas: Interim analysis of the prospective PANCY survey.
2020
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Pezzilli R, Buscarini E, Pollini T, Bonamini D, Marchegiani G +40 more
Plain English This study looked at how doctors evaluate cystic tumors in the pancreas by analyzing data from over 1,300 patients. They found that most of these tumors (about 89.9%) were a specific type called intraductal papillary mucinous neoplasm (IPMN), and only a small number of patients (5.7%) needed surgery after testing. Understanding these trends helps doctors make better decisions on diagnosing and treating pancreatic cysts.
Who this helps: This benefits doctors and patients with pancreatic cystic neoplasms.
Efficacy of a novel self-assembling peptide hemostatic gel as rescue therapy for refractory acute gastrointestinal bleeding.
2020
Endoscopy
de Nucci G, Reati R, Arena I, Bezzio C, Devani M +8 more
Plain English This study looked at a new gel called PuraStat, designed to help stop severe bleeding in the stomach and intestines when standard treatments fail. Out of 77 patients tested, PuraStat worked successfully to stop the bleeding in 90.9% of cases, with only 10.4% experiencing a recurrence of bleeding afterward. This matters because it provides a promising new option for managing difficult gastrointestinal bleeding, which can be life-threatening.
Who this helps: This helps patients with severe gastrointestinal bleeding and doctors treating them.
Endoscopic ultrasound-guided gallbladder drainage in pancreatic cancer and cholangitis: A case report.
2020
World journal of gastrointestinal endoscopy
de Nucci G, Imperatore N, Picascia D, Mandelli ED, Bezzio C +4 more
Plain English This paper reports on a case where a doctor used a special ultrasound technique to drain bile from the gallbladder of an 84-year-old woman with advanced pancreatic cancer and severe bile duct infection (cholangitis). The patient had problems with her existing treatment, but after using endoscopic ultrasound to place a stent, she was able to eat again within 48 hours and left the hospital a week later. This approach showed that alternative methods can effectively address serious complications in patients with cancer, improving their quality of life.
Who this helps: This helps patients with advanced pancreatic cancer and complications like cholangitis.
Endoscopic ultrasound-guided radiofrequency ablation of pancreatic neuroendocrine tumors: a case series.
2020
Endoscopy international open
de Nucci G, Imperatore N, Mandelli ED, di Nuovo F, d'Urbano C +1 more
Plain English This study examined a new treatment method called endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) for small pancreatic neuroendocrine tumors (P-NETs) in ten patients, average age 78.6 years. The treatment successfully removed all tumors in a single session, with no serious side effects reported, and the patients experienced a typical hospital stay of about four days. This is significant because it offers a less invasive treatment option for P-NETs, reducing the risks associated with traditional surgery.
Who this helps: This helps patients with small pancreatic neuroendocrine tumors.
Endoscopic ultrasound-guided radiofrequency ablation of pancreatic neuroendocrine tumors: a systematic review of the literature.
2020
Endoscopy international open
Imperatore N, de Nucci G, Mandelli ED, de Leone A, Zito FP +2 more
Plain English This study looked at a treatment called endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) for patients with pancreatic neuroendocrine tumors (P-NETs). Out of 61 patients treated, 96% showed positive results from the procedure, and only 13.7% experienced mild adverse events. The findings suggest that EUS-RFA is a safe and effective option, especially for smaller tumors under 18 mm, which had an 80% chance of responding to the treatment.
Who this helps: This helps patients with small pancreatic tumors by offering a less invasive treatment option.